Investor Relations

Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of  patients with elevated LDL-C.

Esperion Therapeutics is a publicly traded company (since 2013) and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Esperion Therapeutics (NASDAQ: ESPR) 4:00 PM ET on Jun 24, 2016
Last Price Change Open Day High 52-Week High
16.12
0.78  down   (4.615%) 15.80 17.15 100.98
Volume Previous Close Day Low 52-Week Low
886,092 16.90 15.51 12.61

View all »   RSSRecent Releases

May 4, 2016
Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2016 Financial Results

Mar 8, 2016
Esperion Therapeutics to Present at the Barclays Global Healthcare Conference